VedaBio vs athenahealth

Side-by-side comparison of AI visibility scores, market position, and capabilities

athenahealth leads in AI visibility (95 vs 45)
VedaBio logo

VedaBio

ChallengerHealthcare

General

Precision genome editing biotech developing base and prime editors for rare genetic diseases; improved specificity over first-generation CRISPR competing with Beam Therapeutics and Intellia.

AI VisibilityBeta
Overall Score
C45
Category Rank
#147 of 1158
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
44
Perplexity
43
Gemini
55

About

Veda Bio is a biotechnology company developing novel therapeutics for rare genetic diseases and cancer using its proprietary precision genome editing platform — enabling targeted genetic corrections with greater specificity and reduced off-target editing compared to first-generation CRISPR tools. Founded in 2019 and headquartered in Seattle, Washington, Veda Bio was founded by genome editing pioneers and has raised early-stage funding to develop its differentiated editing technology platform.\n\nVeda Bio's platform focuses on delivering precision genetic medicine that can address root causes of genetic diseases rather than managing symptoms. The company's approach aims to improve on first-generation CRISPR-Cas9 by developing base editors and prime editors that can make specific genetic corrections (single letter DNA changes, small insertions or deletions) without introducing double-strand DNA breaks that create higher off-target editing risk. This precision is critical for therapeutic applications where off-target genomic changes could have serious safety consequences.\n\nIn 2025, Veda Bio operates in the competitive genome editing therapeutics space alongside Intellia Therapeutics, Beam Therapeutics (base editing pioneer), Prime Medicine, and CRISPR Therapeutics. The genome editing field experienced a landmark moment in 2023 with the FDA approval of Casgevy (the first CRISPR-based therapy, for sickle cell disease and beta-thalassemia, developed by Vertex and CRISPR Therapeutics) — validating the genome editing therapeutic modality and creating competitive pressure for improved precision editing platforms. Veda Bio's 2025 strategy focuses on advancing lead programs in rare genetic indications through preclinical development toward IND applications, publishing research to establish scientific credibility, and exploring partnerships or licensing with larger biopharmaceuticals for clinical development.

Full profile
athenahealth logo

athenahealth

LeaderHealthcare

Cloud EHR

$1.7B annual revenue; 160K+ providers, 117M patients; 18.15% EHR market share; 6,713+ companies using 2025; acquired by Bain Capital & Hellman & Friedman Nov 2021 at $17B; AI interoperability 2025

AI VisibilityBeta
Overall Score
A95
Category Rank
#1 of 1
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
95
Gemini
91

About

athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on the principle that healthcare administration should be managed as a service — with athenahealth absorbing the complexity of payer rule updates, regulatory compliance, and billing workflows so that physicians and clinical staff can focus entirely on patient care. Its cloud-native architecture, deployed before most EHR competitors moved to the cloud, remains a core technical differentiator.\n\nathenahealth's platform — athenaOne — integrates EHR, revenue cycle management, patient engagement, and care coordination in a single system used by over 160,000 providers across 117 million patient records. The company serves ambulatory practices ranging from solo physicians to large health systems and medical groups. Its continuously updated rules engine processes millions of payer transactions daily, enabling higher clean claim rates and faster reimbursement compared to on-premise EHR alternatives. athenahealth holds an 18.15% share of the US ambulatory EHR market.\n\nathenahealth is currently owned by a private equity consortium of Bain Capital and Hellman & Friedman, which acquired the company in 2019 for $5.7 billion. Annual revenue stands at approximately $1.7 billion. The company competes with Epic, eClinicalWorks, and Oracle Health in the ambulatory EHR market. Its managed-service model, shared payer network data, and cloud-native infrastructure continue to make it a compelling choice for ambulatory providers who prioritize revenue cycle performance and reduced administrative burden.

Full profile

AI Visibility Head-to-Head

45
Overall Score
95
#147
Category Rank
#1
71
AI Consensus
71
stable
Trend
stable
44
ChatGPT
92
43
Perplexity
95
55
Gemini
91
48
Claude
99
48
Grok
86

Key Details

Category
General
Cloud EHR
Tier
Challenger
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only athenahealth
Cloud EHR

Integrations

Only athenahealth

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.